XML 42 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration Agreements And In-Licensing Arrangements (Tables)
 3 Months Ended
Apr. 02, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Collaborative Revenues Under Collaboration Agreement
Revenues under the collaboration agreement with Ipsen were as follows (in thousands):
Three Months Ended March 31,
20212020
License revenues$22,451 $17,949 
Collaboration services revenues11,355 11,087 
Total$33,806 $29,036 
Revenues under the collaboration agreement with Takeda were as follows (in thousands):
Three Months Ended March 31,
20212020
License revenues$1,301 $— 
Collaboration services revenues4,135 1,069 
Total$5,436 $1,069 
License revenues under the collaboration agreement with Genentech were as follows (in thousands):
 
Three Months Ended March 31,
 
20212020
Profits on U.S. commercialization$1,794 $1,407 
Royalty revenues on ex-U.S. sales$951 $1,309